tradingkey.logo
tradingkey.logo

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the USA

ReutersApr 29, 2025 12:17 PM

- Cullinan Therapeutics Inc CGEM.O:

  • CULLINAN THERAPEUTICS TO INITIATE STUDY OF CLN-978, A BISPECIFIC CD19 T CELL ENGAGER ADMINISTERED SUBCUTANEOUSLY, IN PATIENTS WITH SJÖGREN’S DISEASE IN THE UNITED STATES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI